Loading...
Baxter Pharmaceuticals India Private Limited — Metoclopramide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #3 for Metoclopramide · $947.6K export value · DGFT Verified
Baxter Pharmaceuticals India Private Limited is the #3 Indian exporter of Metoclopramide with $947.6K in export value and 35 verified shipments. Baxter Pharmaceuticals India Private Limited holds a 4.2% market share in Metoclopramide exports across 6 countries. The company exports 5 pharmaceutical products worth $19.6M across 4 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $472.8K | 15 | 57.8% |
| CANADA | $145.5K | 8 | 17.8% |
| NEW ZEALAND | $120.7K | 7 | 14.8% |
| BELGIUM | $58.0K | 2 | 7.1% |
| IRAQ | $20.4K | 1 | 2.5% |
| SLOVAK REPUBLIC | $49 | 2 | 0.0% |
Baxter Pharmaceuticals India Private Limited exports Metoclopramide to 6 countries. The largest destination is AUSTRALIA accounting for 57.8% of Baxter Pharmaceuticals India Private Limited's Metoclopramide shipments, followed by CANADA (17.8%) and NEW ZEALAND (14.8%). These destinations reflect Baxter Pharmaceuticals India Private Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BAXTER HEALTHCARE PTY. LIMITED | AUSTRALIA | $320.7K | 11 |
| BAXTER HEALTHCARE PTY LIMITED | AUSTRALIA | $152.1K | 4 |
| BAXTER CORPORATION CANADA | CANADA | $145.5K | 8 |
| BAXTER HEALTHCARE LTD | NEW ZEALAND | $53.7K | 5 |
| BAXTER DISTRIBUTION CENTRE EUROPE S | BELGIUM | $38.1K | 1 |
India exported $11.2M worth of Metoclopramide through 2,053 shipments from 321 suppliers to 126 countries, serving 568 buyers globally. Baxter Pharmaceuticals India Private Limited contributes $947.6K to this total, accounting for 4.2% of India's Metoclopramide exports. Baxter Pharmaceuticals India Private Limited ships Metoclopramide to 6 countries through 10 buyers.
Baxter Pharmaceuticals India Private Limited's average Metoclopramide shipment value is $27.1K per consignment, based on 35 shipments totaling $947.6K. The largest destination is AUSTRALIA (57.8% of Baxter Pharmaceuticals India Private Limited's Metoclopramide exports).
Baxter Pharmaceuticals India Private Limited ranks #3 among 321 Indian Metoclopramide exporters with a 4.2% market share. The top 3 exporters are IPCA LABORATORIES LIMITED ($5.1M), AVET LIFESCIENCES PRIVATE LIMITED ($1.5M), BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ($947.6K). Baxter Pharmaceuticals India Private Limited processed 35 shipments to 6 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| METOCLOPRAMIDE HCL 5MG/ML SOLUTION FOR INJECTION 2ML GLASS AMPOULE | $377.9K | 15 |
| METOCLOPRAMIDE HCL 5MG/ML SOLUTION FOR INJECTION 2ML GLASS AMPOULENOS | $65.3K | 3 |
| METOCLOPRAMIDE HCL 5MG/ML SOLUTION FOR I | $50.0K | 1 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION5MG/ML 2 ML GLASS VIAL CA | $50.0K | 1 |
| METOCLOPRAMIDE HYDROCHLORIDE INJECTION5MG/ML 2 ML GLASS VIAL | $50.0K | 1 |
| METOCLOPRAMIDE 5MG ML SOLUTION INJECTION2ML GLASS AMPOULE | $38.1K | 1 |
| METOCLOPRAMIDE HCL 5MG MISOLUTION FOR INJECTION 2ML GLASS AMPOULE | $35.8K | 1 |
| METOCLOPRAMIDE HCL 5MG/MLSOLUTION FOR INJ 2ML GLASS AMPOULE | $33.6K | 1 |
What Baxter Pharmaceuticals India Private Limited must comply with to export Metoclopramide to its top destination countries
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | IPCA LABORATORIES LIMITED | $5.1M | 102 | 8 | $50.0K |
| 2 | AVET LIFESCIENCES PRIVATE LIMITED | $1.5M | 30 | 1 | $50.0K |
| 3 | BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED ★ | $947.6K | 35 | 6 | $27.1K |
| 5 | LINCOLN PHARMACEUTICALS LTD | $887.8K | 19 |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 264 | 12.9% |
| SAHAR AIR | 223 | 10.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 199 | 9.7% |
| DELHI AIR CARGO ACC (INDEL4) | 147 | 7.2% |
| JNPT/ NHAVA SHEVA SEA | 120 | 5.8% |
| DELHI AIR | 87 | 4.2% |
| JNPT | 80 | 3.9% |
| AHEMDABAD ICD | 80 | 3.9% |
Baxter Pharmaceuticals India Private Limited also exports these gastrointestinal products. Each links to the detailed product page.
BPIPL's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing transit times and costs for Indian exporters. Such challenges necessitate strategic logistics planning to maintain supply chain efficiency.
Conversely, the India-European Union Free Trade Agreement (FTA), signed in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development offers BPIPL enhanced access to European markets, potentially boosting export volumes and revenues. (en.wikipedia.org)
Additionally, the U.S. FDA's warning letter to BPIPL in July 2023 underscores the importance of stringent quality compliance. Addressing such regulatory concerns is crucial for maintaining market access and reputation. (fda.gov)
Compliance with international regulatory standards is paramount for BPIPL. The FDA's 2023 warning letter highlighted significant violations of Current Good Manufacturing Practice (CGMP) regulations at BPIPL's Ahmedabad facility. Proactive measures to rectify these issues are essential to ensure continued market access and uphold the company's reputation. (fda.gov)
Furthermore, the EU's Falsified Medicines Directive mandates rigorous tracking and verification of pharmaceutical products. BPIPL must align its operations with these requirements to capitalize on the opportunities presented by the India-EU FTA.
Baxter Pharmaceuticals India Private Limited exports 5 products worth $19.6M. Beyond Metoclopramide, top products include Ondansetron, Furosemide, Tobramycin, Imipenem. View the complete Baxter Pharmaceuticals India Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Metoclopramide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Baxter Pharmaceuticals India Private Limited's Metoclopramide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Baxter Pharmaceuticals India Private Limited
Full Company Profile →
5 products · $19.6M total trade · 4 categories
| NEW ZEALAND |
| $36.0K |
| 1 |
| BAXTER HEALTHCARE LIMITED | NEW ZEALAND | $30.9K | 1 |
| BATEEN PHARMA SCIENTIFIC DRUG BUREAU | IRAQ | $20.4K | 1 |
| BAXTER DISTRIBUTION CENTRE EUROPE | BELGIUM | $19.9K | 1 |
| EL SPOL LAB | SLOVAK REPUBLIC | $49 | 2 |
Baxter Pharmaceuticals India Private Limited supplies Metoclopramide to 10 buyers globally. The largest buyer is BAXTER HEALTHCARE PTY. LIMITED (AUSTRALIA), followed by BAXTER HEALTHCARE PTY LIMITED (AUSTRALIA) and BAXTER CORPORATION CANADA (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| METOCLOPRAMIDE HCL 5MG/MLSOLUTION FOR INJECTION 2ML GLASS AMPOULE | $30.9K | 1 |
| METOCLOPRAMIDE 5MG/ML 2ML GV CA AIN03229DETAILS AS PER INVOICE | $30.3K | 3 |
Baxter Pharmaceuticals India Private Limited exports 15 distinct Metoclopramide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is METOCLOPRAMIDE HCL 5MG/ML SOLUTION FOR INJECTION 2ML GLASS A with 15 shipments worth $377.9K.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 5 |
| $46.7K |
| 6 | ADCOCK INGRAM LIMITED | $536.0K | 105 | 1 | $5.1K |
Baxter Pharmaceuticals India Private Limited ranks #3 among 321 Indian Metoclopramide exporters. Average shipment value of $27.1K compared to the market average of $34.8K. The closest competitors by value are IPCA LABORATORIES LIMITED and AVET LIFESCIENCES PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 126+ countries, 568+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Baxter Pharmaceuticals India Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Metoclopramide. For current shipment-level data, contact TransData Nexus.